Skip to main content
Top
Published in: BMC Immunology 1/2014

Open Access 01-12-2014 | Research article

Early changes of the kinetics of monocyte trem-1 reflect final outcome in human sepsis

Authors: Androniki Marioli, Marina Koupetori, Maria Raftogiannis, Maria Patrani, Nikolaos Antonakos, Maria Pavlaki, Georgios Adamis, Georgia Dougekou, Georgia Damoraki, Iraklis Tsangaris

Published in: BMC Immunology | Issue 1/2014

Login to get access

Abstract

Background

TREM-1 (triggering receptor expressed on myeloid cells), a receptor expressed on neutrophils and monocytes, is upregulated in sepsis and seems to tune the inflammatory response. We explored the expression of TREM-1 at the gene level and on cell membranes of monocytes and association with clinical outcome.

Methods

Peripheral venous blood was sampled from 75 septic patients (39 patients with sepsis, 25 with severe sepsis and 11 with septic shock) on sepsis days 1, 3 and 7. TREM-1 on monocytes was measured by flow cytometry; gene expression of TREM-1 in circulating mononuclear cells was assessed by real-time PCR. sTREM-1 was measured in serum by an enzyme immunoassay.

Results

Although surface TREM-1, sTREM-1 and TREM-1 gene expression did not differ between sepsis, severe sepsis and septic shock on day 1, survivors had greater expression of surface TREM-1 on days 3 and 7 compared to non-survivors. sTREM-1 on non-survivors decreased on day 3 compared to baseline. Patients with increase of monocyte gene expression of TREM-1 from day 1 to day 3 had prolonged survival compared to patients with decrease of gene expression of TREM-1 from day 1 to day 3 (p: 0.031).

Conclusions

Early decrease of gene expression of TREM-1 in monocytes is associated with poor outcome. A reciprocal decrease of the pro-inflammatory surface receptor TREM-1 linked with sepsis-induced immunosuppression may be part of the explanation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dombrovskiy VY, Martin AA, Sunderram J, Paz HL: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007, 35: 1244-50. 10.1097/01.CCM.0000261890.41311.E9.PubMedCrossRef Dombrovskiy VY, Martin AA, Sunderram J, Paz HL: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007, 35: 1244-50. 10.1097/01.CCM.0000261890.41311.E9.PubMedCrossRef
2.
go back to reference Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R: Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA. 2014, 311: 1308-16. 10.1001/jama.2014.2637.PubMedCrossRef Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R: Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA. 2014, 311: 1308-16. 10.1001/jama.2014.2637.PubMedCrossRef
3.
go back to reference Leligdowicz A, Dodek PM, Norena M, Wong H, Kumar A, Kumar A: Association between source of infection and hospital mortality in patients who have septic shock. Am J Resp Crit Care Med. 2014, 189: 1204-13. 10.1164/rccm.201310-1875OC.PubMedCrossRef Leligdowicz A, Dodek PM, Norena M, Wong H, Kumar A, Kumar A: Association between source of infection and hospital mortality in patients who have septic shock. Am J Resp Crit Care Med. 2014, 189: 1204-13. 10.1164/rccm.201310-1875OC.PubMedCrossRef
4.
go back to reference Arndt P, Abraham E: Immunological therapies for sepsis. Intensive Care Med. 2001, 27 (S1): S104-15. 10.1007/s001340000574.PubMedCrossRef Arndt P, Abraham E: Immunological therapies for sepsis. Intensive Care Med. 2001, 27 (S1): S104-15. 10.1007/s001340000574.PubMedCrossRef
5.
go back to reference Kotsaki A, Giamarellos-Bourboulis EJ: Emerging drugs for the treatment of sepsis. Expert Opin Emerg Drugs. 2012, 17: 379-91. 10.1517/14728214.2012.697151.PubMedCrossRef Kotsaki A, Giamarellos-Bourboulis EJ: Emerging drugs for the treatment of sepsis. Expert Opin Emerg Drugs. 2012, 17: 379-91. 10.1517/14728214.2012.697151.PubMedCrossRef
6.
go back to reference Bouchon A, Dietrich J, Colonna M: Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000, 164: 4991-5. 10.4049/jimmunol.164.10.4991.PubMedCrossRef Bouchon A, Dietrich J, Colonna M: Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000, 164: 4991-5. 10.4049/jimmunol.164.10.4991.PubMedCrossRef
7.
go back to reference Routsi C, Giamarellos-Bourboulis EJ, Antonopoulou A, Kollias S, Siasiakou S, Koronaios A, Zakynthinos S, Armaganidis A, Giamarellou H, Roussos C: Does soluble triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of septic shock?. Clin Exp Immunol. 2005, 142: 62-7. 10.1111/j.1365-2249.2005.02887.x.PubMedPubMedCentralCrossRef Routsi C, Giamarellos-Bourboulis EJ, Antonopoulou A, Kollias S, Siasiakou S, Koronaios A, Zakynthinos S, Armaganidis A, Giamarellou H, Roussos C: Does soluble triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of septic shock?. Clin Exp Immunol. 2005, 142: 62-7. 10.1111/j.1365-2249.2005.02887.x.PubMedPubMedCentralCrossRef
9.
go back to reference Dower K, Ellis DK, Saraf K, Jelinsky SA, Lin LL: Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol. 2008, 180: 3520-34. 10.4049/jimmunol.180.5.3520.PubMedCrossRef Dower K, Ellis DK, Saraf K, Jelinsky SA, Lin LL: Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol. 2008, 180: 3520-34. 10.4049/jimmunol.180.5.3520.PubMedCrossRef
10.
go back to reference Gibot S, Massin F, Marcou M, Taylor V, Stidwill R, Wilson P, Singer M, Bellingan G: TREM-1 promotes survival during septic shock in mice. Eur J Immunol. 2007, 37: 456-66. 10.1002/eji.200636387.PubMedCrossRef Gibot S, Massin F, Marcou M, Taylor V, Stidwill R, Wilson P, Singer M, Bellingan G: TREM-1 promotes survival during septic shock in mice. Eur J Immunol. 2007, 37: 456-66. 10.1002/eji.200636387.PubMedCrossRef
11.
go back to reference Su L, Han B, Liu C, Liang L, Jiang Z, Deng J, Yan P, Jia Y, Feng D, Xie L: Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis. 2012, 12: 157-10.1186/1471-2334-12-157.PubMedPubMedCentralCrossRef Su L, Han B, Liu C, Liang L, Jiang Z, Deng J, Yan P, Jia Y, Feng D, Xie L: Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis. 2012, 12: 157-10.1186/1471-2334-12-157.PubMedPubMedCentralCrossRef
12.
go back to reference Gibot S, Cravoisy A, Kolopp-Sarda MN, Béné MC, Faure G, Bollaert PE: Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med. 2005, 33: 792-6. 10.1097/01.CCM.0000159089.16462.4A.PubMedCrossRef Gibot S, Cravoisy A, Kolopp-Sarda MN, Béné MC, Faure G, Bollaert PE: Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med. 2005, 33: 792-6. 10.1097/01.CCM.0000159089.16462.4A.PubMedCrossRef
13.
go back to reference Giamarellos-Bourboulis EJ, Tsaganos T, Spyridaki E, Mouktaroudi M, Plachouras D, Vaki I, Karagianni V, Antonopoulou A, Veloni V, Giamarellou H: Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Crit Care. 2006, 10: R166-10.1186/cc5111.PubMedPubMedCentralCrossRef Giamarellos-Bourboulis EJ, Tsaganos T, Spyridaki E, Mouktaroudi M, Plachouras D, Vaki I, Karagianni V, Antonopoulou A, Veloni V, Giamarellou H: Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Crit Care. 2006, 10: R166-10.1186/cc5111.PubMedPubMedCentralCrossRef
14.
go back to reference Adib-Conquy M, Cavaillon JM: Compensatory anti-inflammatory response syndrome. Thromb Haemost. 2009, 101: 36-47.PubMed Adib-Conquy M, Cavaillon JM: Compensatory anti-inflammatory response syndrome. Thromb Haemost. 2009, 101: 36-47.PubMed
15.
go back to reference Dimopoulou I, Pelekanou A, Mavrou I, Savva A, Tzanela M, Kotsaki A, Kardara M, Orfanos SE, Kotanidou A, Giamarellos-Bourboulis EJ: Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: correlation with monocyte gene expression. J Crit Care. 2012, 27: 294-300. 10.1016/j.jcrc.2011.06.013.PubMedCrossRef Dimopoulou I, Pelekanou A, Mavrou I, Savva A, Tzanela M, Kotsaki A, Kardara M, Orfanos SE, Kotanidou A, Giamarellos-Bourboulis EJ: Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: correlation with monocyte gene expression. J Crit Care. 2012, 27: 294-300. 10.1016/j.jcrc.2011.06.013.PubMedCrossRef
16.
go back to reference Poukoulidou T, Spyridaki A, Michailidou I, Kopterides P, Pistiki A, Alexiou Z, Chrisofos M, Dimopoulou I, Drimoussis P, Giamarellos-Bourboulis EJ, Koutelidakis I, Marioli A, Mega A, Orfanos SE, Theodorakopoulou M, Tsironis C, Maggina N, Polychronopoulos V, Tsangaris I: TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen. BMC Infect Dis. 2011, 11: 309-10.1186/1471-2334-11-309.PubMedPubMedCentralCrossRef Poukoulidou T, Spyridaki A, Michailidou I, Kopterides P, Pistiki A, Alexiou Z, Chrisofos M, Dimopoulou I, Drimoussis P, Giamarellos-Bourboulis EJ, Koutelidakis I, Marioli A, Mega A, Orfanos SE, Theodorakopoulou M, Tsironis C, Maggina N, Polychronopoulos V, Tsangaris I: TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen. BMC Infect Dis. 2011, 11: 309-10.1186/1471-2334-11-309.PubMedPubMedCentralCrossRef
17.
go back to reference Levy M, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003, 31: 1250-6. 10.1097/01.CCM.0000050454.01978.3B.PubMedCrossRef Levy M, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003, 31: 1250-6. 10.1097/01.CCM.0000050454.01978.3B.PubMedCrossRef
18.
go back to reference Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. A randomized trial. Am J Respir Crit Care Med. 2006, 174: 84-93. 10.1164/rccm.200512-1922OC.PubMedCrossRef Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. A randomized trial. Am J Respir Crit Care Med. 2006, 174: 84-93. 10.1164/rccm.200512-1922OC.PubMedCrossRef
19.
go back to reference Pinson AG, Philbrick JT, Lindbeck GH, Schorling JB: Fever in the clinical diagnosis of acute pyelonephritis. Am J Emerg Med. 1997, 15: 148-51. 10.1016/S0735-6757(97)90087-5.PubMedCrossRef Pinson AG, Philbrick JT, Lindbeck GH, Schorling JB: Fever in the clinical diagnosis of acute pyelonephritis. Am J Emerg Med. 1997, 15: 148-51. 10.1016/S0735-6757(97)90087-5.PubMedCrossRef
20.
go back to reference Calandra T, Cohen J: The international Sepsis Forum Consensus definitions of infections in the intensive care unit. Crit Care Med. 2005, 33: 1639-48. 10.1097/01.CCM.0000168253.91200.83.CrossRef Calandra T, Cohen J: The international Sepsis Forum Consensus definitions of infections in the intensive care unit. Crit Care Med. 2005, 33: 1639-48. 10.1097/01.CCM.0000168253.91200.83.CrossRef
21.
go back to reference Kollef MH: Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. Intensive Care Med. 2003, 29: 147-9. Kollef MH: Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. Intensive Care Med. 2003, 29: 147-9.
22.
go back to reference Wang F, Liu S, Wu S, Zhu Q, Ou G, Liu C, Wang Y, Liao Y, Sun Z: Blocking TREM-1 signaling prolongs survival of mice with Pseudomonas aeruginosa induced sepsis. Cell Immunol. 2012, 272: 251-8. 10.1016/j.cellimm.2011.10.006.PubMedCrossRef Wang F, Liu S, Wu S, Zhu Q, Ou G, Liu C, Wang Y, Liao Y, Sun Z: Blocking TREM-1 signaling prolongs survival of mice with Pseudomonas aeruginosa induced sepsis. Cell Immunol. 2012, 272: 251-8. 10.1016/j.cellimm.2011.10.006.PubMedCrossRef
23.
go back to reference Oku R, Oda S, Nakada TA, Sadahiro T, Nakamura M, Hirayama Y, Abe R, Tateishi Y, Ito M, Iseki T, Hirasawa H: Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS. Cytokine. 2013, 61: 112-7. 10.1016/j.cyto.2012.09.003.PubMedCrossRef Oku R, Oda S, Nakada TA, Sadahiro T, Nakamura M, Hirayama Y, Abe R, Tateishi Y, Ito M, Iseki T, Hirasawa H: Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS. Cytokine. 2013, 61: 112-7. 10.1016/j.cyto.2012.09.003.PubMedCrossRef
24.
go back to reference Tao F, Peng L, Li J, Yao H: Association of serum myeloid cells of soluble triggering receptor-1 level with myocardial dysfunction in patients with severe sepsis. Mediators Inflamm. 2013, 2013: 819246-10.1155/2013/819246.PubMedPubMedCentralCrossRef Tao F, Peng L, Li J, Yao H: Association of serum myeloid cells of soluble triggering receptor-1 level with myocardial dysfunction in patients with severe sepsis. Mediators Inflamm. 2013, 2013: 819246-10.1155/2013/819246.PubMedPubMedCentralCrossRef
25.
go back to reference Oda S, Sadahiro T, Hirayama Y, Abe R, Tateishi Y, Ito M, Iseki T, Hirasawa H: Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS. Cytokine. 2013, 61: 112-7. 10.1016/j.cyto.2012.09.003.PubMedCrossRef Oda S, Sadahiro T, Hirayama Y, Abe R, Tateishi Y, Ito M, Iseki T, Hirasawa H: Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS. Cytokine. 2013, 61: 112-7. 10.1016/j.cyto.2012.09.003.PubMedCrossRef
26.
go back to reference Kwan A, Hubank M, Rashid A, Klein N, Peters MJ: Transcriptional instability during evolving sepsis may limit biomarker based risk stratification. PLoS One. 2013, 8: e60501-10.1371/journal.pone.0060501.PubMedPubMedCentralCrossRef Kwan A, Hubank M, Rashid A, Klein N, Peters MJ: Transcriptional instability during evolving sepsis may limit biomarker based risk stratification. PLoS One. 2013, 8: e60501-10.1371/journal.pone.0060501.PubMedPubMedCentralCrossRef
27.
go back to reference Turrel-Davin F, Venet F, Monnin C, Barbalat V, Cerrato E, Pachot A, Lepape A, Alberti-Segui C, Monneret G: mRNA-based approach to monitor recombinant gamma-interferon restoration of LPS-induced endotoxin tolerance. Crit Care. 2011, 15: R252-10.1186/cc10513.PubMedPubMedCentralCrossRef Turrel-Davin F, Venet F, Monnin C, Barbalat V, Cerrato E, Pachot A, Lepape A, Alberti-Segui C, Monneret G: mRNA-based approach to monitor recombinant gamma-interferon restoration of LPS-induced endotoxin tolerance. Crit Care. 2011, 15: R252-10.1186/cc10513.PubMedPubMedCentralCrossRef
28.
go back to reference Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med. 2003, 348: 138-50. 10.1056/NEJMra021333.PubMedCrossRef Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med. 2003, 348: 138-50. 10.1056/NEJMra021333.PubMedCrossRef
29.
go back to reference Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011, 306: 2594-605. 10.1001/jama.2011.1829.PubMedPubMedCentralCrossRef Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011, 306: 2594-605. 10.1001/jama.2011.1829.PubMedPubMedCentralCrossRef
30.
go back to reference Leentjens J, Kox M, Koch RM, Preijers F, Joosten LA, van der Hoeven JG, Netea M, Pickkers P: Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med. 2012, 186: 838-45. 10.1164/rccm.201204-0645OC.PubMedCrossRef Leentjens J, Kox M, Koch RM, Preijers F, Joosten LA, van der Hoeven JG, Netea M, Pickkers P: Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med. 2012, 186: 838-45. 10.1164/rccm.201204-0645OC.PubMedCrossRef
Metadata
Title
Early changes of the kinetics of monocyte trem-1 reflect final outcome in human sepsis
Authors
Androniki Marioli
Marina Koupetori
Maria Raftogiannis
Maria Patrani
Nikolaos Antonakos
Maria Pavlaki
Georgios Adamis
Georgia Dougekou
Georgia Damoraki
Iraklis Tsangaris
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2014
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-014-0063-y

Other articles of this Issue 1/2014

BMC Immunology 1/2014 Go to the issue